[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Yang W, Chen J, Zhou L: Effects of shear stress on intracellular calcium change and histamine release in rat basophilic leukemia (RBL-2H3) cells. J Environ Pathol Toxicol Oncol; 2009;28(3):223-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of shear stress on intracellular calcium change and histamine release in rat basophilic leukemia (RBL-2H3) cells.
  • Massage, one form of physical therapy, is widely used for a large number of musculoskeletal disorders, but its exact mechanism still remains to be elucidated.
  • One hypothesis is that the shear stress caused by massage may induce cutaneous mast cells to release histamine, thereby improving the local tissue microcirculation of blood.
  • In the present work, a mast cell line (rat basophilic leukemia cells, RBL-2H3) was used in vitro to study cellular responses to the stimulus of shear stress generated by a rotating rotor in a cell dish.
  • Because histamine is a well-known mediator of microvascular tissue dilation, these results may have an important impact on understanding the mechanism involved in massage therapy.
  • [MeSH-minor] Animals. Calcium Channels / drug effects. Calcium Channels / physiology. Calcium Signaling / drug effects. Calcium Signaling / physiology. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / metabolism. Indicators and Reagents / pharmacology. Leukemia, Basophilic, Acute. Microcirculation. Rats. Ruthenium Red / pharmacology. Stress, Mechanical. TRPV Cation Channels / antagonists & inhibitors. TRPV Cation Channels / metabolism

  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19888909.001).
  • [ISSN] 2162-6537
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Indicators and Reagents; 0 / TRPV Cation Channels; 0 / Trpv4 protein, rat; 11103-72-3 / Ruthenium Red; 820484N8I3 / Histamine; SY7Q814VUP / Calcium
  •  go-up   go-down


2. Beck MN, Balmer A, Dessing C, Pica A, Munier F: First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol; 2000 Aug;18(15):2881-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma.
  • PURPOSE: To evaluate the efficacy of first-line chemotherapy (CT) in preventing external-beam radiotherapy (EBR) and/or enucleation in patients with retinoblastoma (Rbl).
  • PATIENTS AND METHODS: Twenty-four patients with newly diagnosed unilateral or bilateral Rbl received CT associated with local treatment (LT).
  • Two to five courses of etoposide and carboplatin were administered at 3- to 4-week intervals, depending on tumor response, and were completed each time by LT.
  • Six other patients with advanced disease (groups IV and V) experienced treatment failure and needed salvage treatment by EBR and/or enucleation.
  • CONCLUSION: CT combined with intensive LT is effective in patients with groups I to III Rbl, permitting the avoidance of EBR in the majority of these young children and, thus, reducing the risk of long-term sequelae.
  • This is in contrast with the disappointing results for patients with groups IV and V Rbl, in whom EBR and/or enucleation was needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eye Enucleation. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Etoposide / administration & dosage. Female. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Retinoblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2001 Nov 1;19(21):4182-3 [11689590.001]
  • (PMID = 10920136.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


3. Baroody FM, Naclerio RM: Antiallergic effects of H1-receptor antagonists. Allergy; 2000;55 Suppl 64:17-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary mechanism of antihistamine action in the treatment of allergic diseases is believed to be competitive antagonism of histamine binding to cellular receptors (specifically, the H1-receptors), which are present on nerve endings, smooth muscles, and glandular cells.
  • This notion is supported by the fact that structurally unrelated drugs antagonize the H1-receptor and provide clinical benefit.
  • On the basis of in vitro and animal experiments, drugs classified as H1-receptor antagonists have long been recognized to have additional pharmacological properties.
  • These additional properties are not uniformly distributed among drugs classified as H1-receptor antagonists.
  • In addition, it inhibits arachidonic acid-induced paw oedema in rats without affecting carrageenin-induced rat paw oedema, suggesting an effect on LT generation.
  • It also inhibits anaphylactic release of histamine from rodent mast cells, LTC4 and LTB4 release from mouse bone-marrow-derived mast cells, LTC4 release from rat intestinal mast cells, and 5-lipoxygenase activity of polymorphonuclear neutrophils of guinea-pig intestines and rat basophilic leukaemia cells.
  • It is equally clear that these antiallergic effects are not uniformly shared among all drugs of this class.
  • [MeSH-major] Anti-Allergic Agents / immunology. Histamine H1 Antagonists / immunology. Histamine H1 Antagonists / therapeutic use. Hypersensitivity / drug therapy. Hypersensitivity / immunology
  • [MeSH-minor] Animals. Benzimidazoles / immunology. Benzimidazoles / therapeutic use. Disease Models, Animal. Humans. Receptors, Histamine H1 / immunology. Rhinitis / drug therapy. Rhinitis / immunology

  • MedlinePlus Health Information. consumer health - Allergy.
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291777.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI45583; United States / NIDCD NIH HHS / DC / DC 02714
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Benzimidazoles; 0 / Histamine H1 Antagonists; 0 / Receptors, Histamine H1; 244O1F90NA / mizolastine
  • [Number-of-references] 34
  •  go-up   go-down


Advertisement
4. Wender PA, Baryza JL, Brenner SE, Clarke MO, Craske ML, Horan JC, Meyer T: Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. Curr Drug Discov Technol; 2004 Jan;1(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bryostatin 1 represents a novel and potent therapeutic lead with a unique activity profile.
  • Function oriented synthesis provides a means to address this supply problem through the design of synthetically more accessible simplified structures that at the same time incorporate improved functional activity.
  • More significantly, the described molecule retains the functional ability to translocate a PKCdelta-GFP fusion protein in RBL cells.
  • [MeSH-major] Drug Design. Macrolides / chemical synthesis. Macrolides / pharmacology. Protein Kinase C / metabolism
  • [MeSH-minor] Animals. Bryostatins. Cell Line, Tumor. Image Processing, Computer-Assisted. Indicators and Reagents. Isoenzymes / chemistry. Isoenzymes / metabolism. Leukemia, Basophilic, Acute / drug therapy. Leukemia, Basophilic, Acute / metabolism. Microscopy, Fluorescence. Models, Molecular. Protein Binding. Rats

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472215.001).
  • [ISSN] 1570-1638
  • [Journal-full-title] Current drug discovery technologies
  • [ISO-abbreviation] Curr Drug Discov Technol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31845; United States / NIMH NIH HHS / MH / MH064801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Bryostatins; 0 / Indicators and Reagents; 0 / Isoenzymes; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


5. Qian C, Hwang SB, Libertine-Garahan L, Eckman JB, Cai X, Scannell RT, Yeh CG: Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res; 2001 Sep;44(3):213-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LDP-392 is 17.9-fold more potent than zileuton (5-LO inhibitor) in the RBL cytosolic 5-LO assay, and equally potent as MK 287 (PAF receptor antagonist) in the human platelet PAF receptor binding assay.
  • [MeSH-minor] Animals. Arachidonate 5-Lipoxygenase / metabolism. Dose-Response Relationship, Drug. Edema / drug therapy. Erythema / drug therapy. Female. Guinea Pigs. Humans. Mice. Rats

  • Hazardous Substances Data Bank. UREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11529688.001).
  • [ISSN] 1043-6618
  • [Journal-full-title] Pharmacological research
  • [ISO-abbreviation] Pharmacol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / CMI 392; 0 / Furans; 0 / Lipoxygenase Inhibitors; 0 / Platelet Activating Factor; 0 / Platelet Membrane Glycoproteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / platelet activating factor receptor; 8W8T17847W / Urea; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  •  go-up   go-down


6. Saito SY, Maruyama Y, Kamiyama S, Nakahata N, Ohizumi Y: Ephedrae herba in Mao-Bushi-Saishin-To inhibits IgE-mediated histamine release and increases cAMP content in RBL-2H3 cells. J Pharmacol Sci; 2004 May;95(1):41-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ephedrae herba in Mao-Bushi-Saishin-To inhibits IgE-mediated histamine release and increases cAMP content in RBL-2H3 cells.
  • Mao as well as MBS but not Saishin nor Bushi inhibited IgE-mediated histamine release from rat basophilic leukemia (RBL-2H3) cells.
  • Consistently, MBS and Mao but not Bushi nor Saishin increased cAMP levels in RBL-2H3 cells.
  • [MeSH-major] Cyclic AMP / biosynthesis. Drugs, Chinese Herbal / pharmacology. Ephedra. Ephedrine / analogs & derivatives. Histamine Release / drug effects. Immunoglobulin E / physiology. Immunosuppressive Agents / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Leukemia, Basophilic, Acute / drug therapy. Leukemia, Basophilic, Acute / immunology. Male. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. (L)-EPHEDRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15153649.001).
  • [ISSN] 1347-8613
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Immunosuppressive Agents; 0 / mao-bushi-saishin-to; 37341-29-0 / Immunoglobulin E; 60VH42A1KJ / N-methylephedrine; E0399OZS9N / Cyclic AMP; GN83C131XS / Ephedrine
  •  go-up   go-down


7. Otsu K, Sato K, Ikeda Y, Imai H, Nakagawa Y, Ohba Y, Fujii J: An abortive apoptotic pathway induced by singlet oxygen is due to the suppression of caspase activation. Biochem J; 2005 Jul 1;389(Pt 1):197-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Singlet oxygen causes the cytotoxic process of tumour cells in photodynamic therapy.
  • To address this issue, we synthesized and used two types of endoperoxides, MNPE (1-methylnaphthalene-4-propionate endoperoxide) and NDPE (naphthalene-1,4-dipropionate endoperoxide), that generate defined amounts of singlet oxygen at 37 degrees C with similar half lives.
  • RBL cells, a rat basophil leukaemia-derived line, that overexpress phospholipid hydroperoxide glutathione peroxidase in mitochondria were found to be highly resistant to the cytotoxic effect of MNPE.
  • MNPE treatment induced much less DNA ladder formation and nuclear fragmentation in cells than etoposide treatment, even though these treatments induced a similar extent of cellular damage.
  • [MeSH-minor] Caspases / metabolism. Cell Line, Tumor. Cell-Free System. Cytochromes c / metabolism. Cytochromes c / secretion. Enzyme Activation / drug effects. Glutathione / metabolism. Humans. Hydrophobic and Hydrophilic Interactions. Lipid Peroxides / pharmacology. Mitochondria / enzymology. Mitochondria / secretion. Molecular Structure. Naphthols / pharmacology. Propionates / pharmacology. Selenium / metabolism. Tocopherols. Vitamin E / analogs & derivatives. Vitamin E / metabolism. beta Carotene / metabolism

  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 2001 Apr 15;30(8):825-35 [11295525.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):29294-302 [10506188.001]
  • [Cites] FEBS Lett. 2001 Jul 6;500(3):114-8 [11445067.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98 [11483992.001]
  • [Cites] Biol Chem. 2002 Mar-Apr;383(3-4):443-56 [12033434.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 15;32(12):1293-303 [12057767.001]
  • [Cites] FEBS Lett. 2002 Sep 11;527(1-3):289-92 [12220676.001]
  • [Cites] Free Radic Biol Med. 2003 Jan 15;34(2):145-69 [12521597.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):3298-307 [12433931.001]
  • [Cites] Biochem J. 2003 May 1;371(Pt 3):1055-64 [12605597.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 6;305(3):761-70 [12763058.001]
  • [Cites] Anal Bioanal Chem. 2003 Jun;376(4):444-7 [12719955.001]
  • [Cites] FASEB J. 2003 Dec;17(15):2202-8 [14656982.001]
  • [Cites] Biochem J. 2004 Jan 1;377(Pt 1):241-8 [14531733.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 19;312(3):843-9 [14680842.001]
  • [Cites] Photochem Photobiol Sci. 2004 Jan;3(1):17-25 [14743273.001]
  • [Cites] Methods Enzymol. 1985;113:548-55 [4088074.001]
  • [Cites] Nucleic Acids Res. 1991 Oct 25;19(20):5792 [1945860.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12365-7 [7809042.001]
  • [Cites] J Biochem. 1996 Apr;119(4):817-22 [8743587.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14586-91 [8962096.001]
  • [Cites] J Cell Biol. 1997 Jan 13;136(1):215-27 [9008715.001]
  • [Cites] FEBS Lett. 1997 May 26;408(3):289-91 [9188778.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25719-23 [9325297.001]
  • [Cites] J Biol Chem. 2000 Mar 3;275(9):6067-70 [10692394.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):2984-9 [10716721.001]
  • [Cites] Methods Enzymol. 2000;319:197-207 [10907511.001]
  • [Cites] Methods Enzymol. 2000;319:342-58 [10907525.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):25939-48 [10837470.001]
  • [Cites] Photochem Photobiol. 2000 Oct;72(4):548-53 [11045728.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] FEBS Lett. 2000 Nov 10;484(3):280-4 [11078893.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):221-32 [10998365.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):183-93 [10998361.001]
  • [Cites] J Exp Med. 1997 Nov 17;186(10):1763-8 [9362536.001]
  • [Cites] FEBS Lett. 1998 Jul 31;432(1-2):9-12 [9710240.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] FEBS Lett. 1998 Nov 20;439(3):329-33 [9845348.001]
  • [Cites] J Invest Dermatol. 1999 Jan;112(1):3-12 [9886256.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4924-33 [9988735.001]
  • [Cites] Eur J Biochem. 1999 Mar;260(3):917-22 [10103024.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11549-56 [10206961.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15345-9 [10336420.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17325-33 [10358093.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):203-12 [10388534.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22686-92 [10428850.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 7;262(3):647-50 [10471379.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):999-1010 [11381085.001]
  • (PMID = 15796713.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3-(4'-methyl-1'-naphthyl)propionic acid 1',4'-endoperoxide; 0 / Caspase Inhibitors; 0 / Lipid Peroxides; 0 / Naphthols; 0 / Propionates; 01YAE03M7J / beta Carotene; 1406-18-4 / Vitamin E; 1406-66-2 / Tocopherols; 17778-80-2 / Singlet Oxygen; 9007-43-6 / Cytochromes c; 97860-59-8 / 3,3'-(1,4-naphthylidene)diproprionate; EC 3.4.22.- / Caspases; GAN16C9B8O / Glutathione; H6241UJ22B / Selenium
  • [Other-IDs] NLM/ PMC1184552
  •  go-up   go-down


8. Perek D, Brozyna A, Dembowska-Baginska B, Stypinska M, Sojka M, Bacewicz L, Polnik D, Kalicinski P: [Tumours in newborns and infants up to three months of life. One institution experience]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):711-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Newborns and infants up to three months of life are a specific group of population in paediatric oncology due to immaturity of tissues and organs and rarity of neoplastic diseases in this group of patients (pts).
  • There are no strict therapeutic procedures established for these children.
  • THE AIM of our study was to examine distribution of tumours in newborns and infants up to 3 months of age treated in our institution and to present our own experience in the treatment of these patients.
  • Distribution of tumour types in newborns and babies from 1 to 3 months of age was analyzed separately.
  • Due to similar growth pattern, response to treatment and it's side effects in newborns and small infants, treatment results were evaluated for the whole group.
  • There were also 3 cases of soft tissue sarcomas (STS), 2 central nervous system tumours (CNS), 2 retinoblastoma (RB), 2 hepatoblastoma (HB).
  • Eleven pts underwent combined treatment of chemotherapy and surgery: 5 with stage III and IV NBL, 6 with other tumours.
  • Chemotherapy alone was administered to 7 pts in whom local advancement of disease enabled surgery and to pts with RBL.
  • Three out of 7 pts are alive all with RBL.
  • One pt, critically ill, died before any treatment.
  • 2. Newborns and small infants with advanced neoplastic disease, similarly to older children can be cured with chemotherapy.
  • 3. Individual approach is warranted in newborns and small infants and treatment should be carried out in specialized centres.
  • 4. All patients who completed treatment of any tumour type should be followed up by a pediatric oncologist.
  • [MeSH-major] Infant Welfare / statistics & numerical data. Neoplasms / epidemiology. Neoplasms / therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317902.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


9. Choi YH, Lim H, Heo MY, Kwon DY, Kim HP: Anti-inflammatory activity of the ethanol extract of Chungkukjang, Korean fermented bean: 5-lipoxygenase inhibition. J Med Food; 2008 Sep;11(3):539-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anti-inflammatory activity of Chungkukjang, a Korean traditional fermented soybean food (Korean-style Natto), was examined for the first time.
  • From the results, it was found that the ethanol extract of Chungkukjang inhibited 5-lipoxygenase from A23187-treated RBL-1 cells, reducing leukoriene production (50% inhibitory concentration = 54.1 microg/mL).
  • Since leukotrienes are intimately involved in some allergic disorders, the anti-allergic activity of Chungkukjang was further examined in animal models of passive cutaneous anaphylaxis (type I hypersensitivity) and arachidonic acid-induced ear edema, two well-known in vivo models sensitive to 5-lipoxygenase inhibitors.
  • [MeSH-major] Inflammation / drug therapy. Inflammation Mediators / metabolism. Isoflavones / therapeutic use. Lipoxygenase Inhibitors / therapeutic use. Plant Extracts / therapeutic use. Soybean Proteins / therapeutic use. Soybeans
  • [MeSH-minor] Animals. Arachidonate 5-Lipoxygenase / metabolism. Arachidonic Acid / metabolism. Ear. Edema / drug therapy. Fermentation. Hypersensitivity / drug therapy. Lipopolysaccharides / pharmacology. Male. Mice. Mice, Inbred ICR. Nitric Oxide / biosynthesis. Phytotherapy. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18800904.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Isoflavones; 0 / Lipopolysaccharides; 0 / Lipoxygenase Inhibitors; 0 / Plant Extracts; 0 / Soybean Proteins; 0 / chungkookjang; 27YG812J1I / Arachidonic Acid; 31C4KY9ESH / Nitric Oxide; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  •  go-up   go-down


10. Lee JY, Jang YW, Kang HS, Moon H, Sim SS, Kim CJ: Anti-inflammatory action of phenolic compounds from Gastrodia elata root. Arch Pharm Res; 2006 Oct;29(10):849-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous screening of the pharmacological action of Gastrodia elata (GE) root (Orchidaceae) showed that methanol (MeOH) extracts have significant anti-inflammatory properties.
  • To investigate the anti-inflammatory and anti-oxidant activity of these compounds, their effects on carrageenan-induced paw edema, arachidonic acid (AA)-induced ear edema and analgesic activity in acetic acid (HAc)-induced writhing response were carried out in vivo; cyclooxygenase (COX) activity, reactive oxygen species (ROS) generation in rat basophilic leukemia (RBL 2H3) cells and 1,1-diphenyl-2-picryl-hydroazyl (DPPH) scavenging activity were determined in vitro.
  • [MeSH-minor] Acetic Acid. Animals. Anti-Inflammatory Agents / chemistry. Anti-Inflammatory Agents / pharmacology. Arachidonic Acid. Benzyl Compounds / chemistry. Benzyl Compounds / pharmacology. Carrageenan. Dose-Response Relationship, Drug. Ear, External / drug effects. Ear, External / pathology. Edema / chemically induced. Edema / drug therapy. Hindlimb / drug effects. Hindlimb / pathology. Inflammation / chemically induced. Inflammation / prevention & control. Male. Methanol. Molecular Structure. Pain / chemically induced. Pain / drug therapy. Plant Extracts / chemistry. Plant Extracts / pharmacology. Prostaglandin-Endoperoxide Synthases / metabolism. Quantitative Structure-Activity Relationship. Rats. Rats, Sprague-Dawley. Reactive Oxygen Species / antagonists & inhibitors. Reactive Oxygen Species / metabolism

  • Hazardous Substances Data Bank. ACETIC ACID .
  • Hazardous Substances Data Bank. METHANOL .
  • Hazardous Substances Data Bank. CARRAGEENAN GUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121179.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Benzyl Compounds; 0 / Cyclooxygenase Inhibitors; 0 / Phenols; 0 / Plant Extracts; 0 / Reactive Oxygen Species; 27YG812J1I / Arachidonic Acid; 9000-07-1 / Carrageenan; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; Q40Q9N063P / Acetic Acid; Y4S76JWI15 / Methanol
  •  go-up   go-down


11. Joo SS, Kim SG, Choi SE, Kim YB, Park HY, Seo SJ, Choi YW, Lee MW, Lee DI: Suppression of T cell activation by hirsutenone, isolated from the bark of Alnus japonica, and its therapeutic advantages for atopic dermatitis. Eur J Pharmacol; 2009 Jul 1;614(1-3):98-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of T cell activation by hirsutenone, isolated from the bark of Alnus japonica, and its therapeutic advantages for atopic dermatitis.
  • The increasing prevalence and severity of atopic dermatitis during recent decades has prompted the development of safe and more highly effective drugs.
  • Although topical corticosteroids have been used for more than 50 years as first line therapy for atopic dermatitis, their potential side effects limits their clinical uses.
  • In light of this, steroid-free topical calcineurin inhibitors were developed and have been used in patients with moderate to severe atopic dermatitis.
  • In the present study, we examined if hirsutenone suppressed the profiles of atopic dermatitis development in vitro via mimicry of calcineurin inhibitor actions in mouse splenocytes and RBL-2H3 mast cells.
  • Therefore, our results suggest that hirsutenone may be a new topical drug candidate, which probably acts by mimicking calcineurin inhibitor mechanisms.
  • [MeSH-major] Alnus / chemistry. Catechols / isolation & purification. Catechols / pharmacology. Dermatitis, Atopic / drug therapy. Dermatitis, Atopic / immunology. Diarylheptanoids / isolation & purification. Diarylheptanoids / pharmacology. Plant Bark / chemistry. T-Lymphocytes / drug effects
  • [MeSH-minor] Animals. Antibodies / immunology. Antigens, CD3 / immunology. Biomarkers / metabolism. Biomimetics. Calcineurin Inhibitors. Cell Proliferation / drug effects. Cytokines / antagonists & inhibitors. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Immunosuppressive Agents / isolation & purification. Immunosuppressive Agents / pharmacology. Immunosuppressive Agents / therapeutic use. Interleukin-2 Receptor alpha Subunit / antagonists & inhibitors. Lymphocyte Activation / drug effects. Mast Cells / drug effects. Mast Cells / secretion. Mice. NFATC Transcription Factors / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Signal Transduction / drug effects. Th1 Cells / drug effects. Th2 Cells / drug effects. beta-N-Acetylhexosaminidases / secretion

  • Genetic Alliance. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409888.001).
  • [ISSN] 1879-0712
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD3; 0 / Biomarkers; 0 / Calcineurin Inhibitors; 0 / Catechols; 0 / Cytokines; 0 / Diarylheptanoids; 0 / Immunosuppressive Agents; 0 / Interleukin-2 Receptor alpha Subunit; 0 / NFATC Transcription Factors; 0 / RNA, Messenger; 0 / hirsutenone; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


12. McCloud JM, Jameson JS, Scott AN: Life-threatening sepsis following treatment for haemorrhoids: a systematic review. Colorectal Dis; 2006 Nov;8(9):748-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Life-threatening sepsis following treatment for haemorrhoids: a systematic review.
  • Treatments such as rubber band ligation (RBL), sclerotherapy and excisional surgery have been in use for many years, and recently stapled haemorrhoidopexy, or procedure for prolapsing haemorrhoids (PPH) has gained acceptance.
  • The purpose of this review was to assess the scale of the problem, and identify any predisposing factors, common presenting features, and treatment options in those who suffer these complications.
  • Of these, 17 had undergone RBL, three had sclerotherapy, one had cryotherapy, 10 had excisional surgery and seven had PPH.
  • Most were managed by means of surgery, although a minority survived having received conservative therapy.
  • With the exception of two patients (one of whom was human immunodeficiency virus positive and the other had a drug-induced agranulocytosis) all were well prior to surgery.
  • CONCLUSIONS: Although extremely uncommon, severe sepsis does occur post-treatment for haemorrhoids and all surgeons who treat such patients should be aware of the potential complications and alert to their presenting features.
  • Early presentation without evidence of tissue necrosis may be managed conservatively, although most cases are managed by means of surgery.
  • [MeSH-minor] Gangrene / etiology. Gangrene / therapy. Humans

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Hemorrhoids.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17032319.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  •  go-up   go-down


13. Shinomiya F, Hamauzu Y, Kawahara T: Anti-allergic effect of a hot-water extract of quince (Cydonia oblonga). Biosci Biotechnol Biochem; 2009 Aug;73(8):1773-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the effect of a crude hot-water extract (HW) of quince (Cydonia oblonga Miller) fruit on type I allergy in vivo and in vitro.
  • Moreover, we found that quince HW inhibited the release of beta-hexosaminidase from rat basophilic leukemia cell line RBL-2H3 after a 24-h treatment.
  • These results suggest that quince HW had an inhibitory effect on type I allergy by suppressing IgE production and IgE-mediated degranulation.
  • [MeSH-minor] Administration, Oral. Animals. Cell Line, Tumor. Dermatitis, Atopic / blood. Dermatitis, Atopic / drug therapy. Humans. Immunoglobulin E / blood. Male. Mice. Phytotherapy. Rats. Receptors, IgE / metabolism. Skin / drug effects. Skin / pathology. beta-N-Acetylhexosaminidases / metabolism

  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661701.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Plant Extracts; 0 / Receptors, IgE; 059QF0KO0R / Water; 37341-29-0 / Immunoglobulin E; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


14. Di Marzo V, Melck D, De Petrocellis L, Bisogno T: Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat; 2000 Apr;61(1-2):43-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biosynthesis of AEA, PEA, or 2-AG can be induced by stimulation with either Ca(2+) ionophores, lipopolysaccharide, or platelet activating factor in macrophages, and by ionomycin or antigen challenge in rat basophilic leukemia (RBL-2H3) cells (a widely used model for mast cells).
  • AEA and PEA modulate cytokine and/or arachidonate release from macrophages in vitro, regulate serotonin secretion from RBL-2H3 cells, and are analgesic in some animal models of inflammatory pain.
  • [MeSH-minor] Adjuvants, Immunologic / metabolism. Adjuvants, Immunologic / pharmacology. Animals. Anti-Inflammatory Agents, Non-Steroidal / chemistry. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Cannabinoids / metabolism. Cell Division / drug effects. Endocannabinoids. Ethanolamines. Humans. Male. Polyunsaturated Alkamides. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / metabolism. Rats. Receptors, Growth Factor / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10785541.001).
  • [ISSN] 1098-8823
  • [Journal-full-title] Prostaglandins & other lipid mediators
  • [ISO-abbreviation] Prostaglandins Other Lipid Mediat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Arachidonic Acids; 0 / Cannabinoids; 0 / Endocannabinoids; 0 / Ethanolamines; 0 / Glycerides; 0 / Palmitic Acids; 0 / Polyunsaturated Alkamides; 0 / Receptors, Growth Factor; 53847-30-6 / 2-arachidonylglycerol; 6R8T1UDM3V / palmidrol; 94421-68-8 / anandamide
  • [Number-of-references] 99
  •  go-up   go-down


15. Li L, Ji H, Sheng L, Zhang Y, Lai Y, Chen X: The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Pharmacol; 2009 Apr 1;607(1-3):244-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It also inhibited the production of thromboxane B(2) and prostaglandin E(2) in calcium ionophore A23187-induced human (IC(50)=0.50 microM) and rat whole blood (IC(50)=0.93 microM), and rat peritoneal leukocytes (IC(50)=2.27 microM).
  • ZLJ-6 suppressed the activity of 5-lipoxygenase in the rat basophilic leukemia (RBL-1) cell lysate (IC(50)=0.32 microM) and in intact cells (IC(50)=1.06 microM) and reduced the generation of leukotriene B(4) (LTB(4)) in A23187-stimulated human (IC(50)=1.61 microM) or rat whole blood (IC(50)=0.99 microM), and rat peritoneal leukocytes (IC(50)=2.59 microM).
  • Thus ZLJ-6 is an ideal substitute for classical non-steroidal anti-inflammatory therapy.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Cyclooxygenase Inhibitors / pharmacology. Edema / drug therapy. Imidazoles / pharmacology. Sulfones / pharmacology
  • [MeSH-minor] Administration, Oral. Animals. Carrageenan. Cyclooxygenase 1 / drug effects. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / drug effects. Cyclooxygenase 2 / metabolism. Dinoprostone / antagonists & inhibitors. Disease Models, Animal. Female. Humans. Inhibitory Concentration 50. Leukocytes / drug effects. Leukocytes / metabolism. Leukotriene B4 / antagonists & inhibitors. Lipoxygenase Inhibitors / administration & dosage. Lipoxygenase Inhibitors / pharmacology. Lipoxygenase Inhibitors / toxicity. Male. Rats. Rats, Sprague-Dawley. Thromboxane B2 / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Edema.
  • Hazardous Substances Data Bank. CARRAGEENAN GUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243697.001).
  • [ISSN] 1879-0712
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 1-methyl-1,5-dihydro-2-amino-5-(4-(mesyl)benzylidene)-4H-imidazole-4-one; 0 / Anti-Inflammatory Agents; 0 / Cyclooxygenase Inhibitors; 0 / Imidazoles; 0 / Lipoxygenase Inhibitors; 0 / Sulfones; 1HGW4DR56D / Leukotriene B4; 54397-85-2 / Thromboxane B2; 9000-07-1 / Carrageenan; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


16. Cui Y, Hou X, Chen J, Xie L, Yang L, Le Y: Sesamin inhibits bacterial formylpeptide-induced inflammatory responses in a murine air-pouch model and in THP-1 human monocytes. J Nutr; 2010 Feb;140(2):377-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarly, sesamin inhibited FPR-transfected rat basophilic leukemia cell [epitope-tagged human FPR (ETFR) cell] migration toward fMLF (P < 0.01).
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Chemotaxis, Leukocyte / drug effects. Dioxoles / pharmacology. Leukemic Infiltration / drug therapy. Lignans / pharmacology. Monocytes / drug effects. Plant Extracts / pharmacology. Sesamum / chemistry
  • [MeSH-minor] Animals. Bacteria / metabolism. Basophils / drug effects. Bucladesine. Calcium / metabolism. Cell Line. Cell Line, Tumor. Dose-Response Relationship, Drug. Humans. Inflammation / chemically induced. Inflammation / drug therapy. Inflammation / metabolism. Leukemia / drug therapy. Mice. Mice, Inbred C57BL. Mitogen-Activated Protein Kinase 1 / metabolism. Models, Animal. N-Formylmethionine Leucyl-Phenylalanine. NF-kappa B / antagonists & inhibitors. Phosphorylation. Phytotherapy. Rats. Receptors, Formyl Peptide / metabolism. Signal Transduction / drug effects

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032476.001).
  • [ISSN] 1541-6100
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Dioxoles; 0 / Lignans; 0 / NF-kappa B; 0 / Plant Extracts; 0 / Receptors, Formyl Peptide; 59880-97-6 / N-Formylmethionine Leucyl-Phenylalanine; 63X7MBT2LQ / Bucladesine; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; S7946O4P76 / sesamin; SY7Q814VUP / Calcium
  •  go-up   go-down


17. Zhu CB, Steiner JA, Munn JL, Daws LC, Hewlett WA, Blakely RD: Rapid stimulation of presynaptic serotonin transport by A(3) adenosine receptors. J Pharmacol Exp Ther; 2007 Jul;322(1):332-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using rat basophilic leukemia 2H3 cell line (RBL-2H3), we previously established that activation of A(3) adenosine receptors (A(3)AR) stimulates SERT activity via both PKG and p38 MAPK (Zhu et al., 2004a).
  • As in RBL-2H3 cells, IB-MECA stimulation of synaptosomal 5-HT uptake can be blocked by preincubation with PKG antagonists N-[2-(methylamino)ethy]-5-isoquinoline-sulfonamide (H8) and DT-2 (YGRKKRRQRRRPPLRK(5)H), as well as by the p38 MAPK inhibitor SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole].
  • Chronoamperometry studies in the anesthetized rat hippocampus support a role for A(3)ARs in SERT regulation in vivo.
  • Together, these results identify a novel, region-specific action of CNS A(3)ARs in the modulation of SERT-mediated 5-HT transport that may be relevant for the etiology and/or therapy of 5-HT-linked brain disorders.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Adenosine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460150.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA07390
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Adenosine A3; 0 / Serotonin Plasma Membrane Transport Proteins; 152918-18-8 / N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; 20125-40-0 / N-(1-methyl-2-phenylethyl)adenosine; 333DO1RDJY / Serotonin; 35920-39-9 / Adenosine-5'-(N-ethylcarboxamide); EC 2.7.11.12 / Cyclic GMP-Dependent Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; K72T3FS567 / Adenosine
  •  go-up   go-down


18. Knipping K, van Esch EC, Wijering SC, van der Heide S, Dubois AE, Garssen J: In vitro and in vivo anti-allergic effects of Arctium lappa L. Exp Biol Med (Maywood); 2008 Nov;233(11):1469-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The discovery of drugs that can be used for the treatment of allergic disease is important in human health.
  • AL was selected out of 10,000 herbal extracts in a set-up for high throughput screening in which the degree of degranulation was monitored by the release of beta-hexosaminidase from rat basophil leukemia (RBL-2H3) cells.
  • Although arctiin, the active component of AL that has been described in the literature, was not able to reduce degranulation in RBL-2H3 cells, a single high-performance liquid chromatography (HPLC) fraction from the AL extract inhibited beta-hexosaminidase release (IC(50) = 22.2 microg/ml).
  • In addition, this active component was able to inhibit acute skin response in mice in vivo, indicating that AL is a very promising natural component for use in anti-allergic treatment.
  • [MeSH-minor] Animals. Basophil Degranulation Test. Basophils / drug effects. Basophils / metabolism. Chemical Fractionation. Chromatography, High Pressure Liquid. Ear Diseases / chemically induced. Ear Diseases / drug therapy. Edema / chemically induced. Edema / drug therapy. Humans. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism. Leukotrienes / biosynthesis. Mice. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703753.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Anti-Inflammatory Agents; 0 / Leukotrienes; 0 / Plant Extracts
  •  go-up   go-down


19. Liu X, Groschner K, Ambudkar IS: Distinct Ca(2+)-permeable cation currents are activated by internal Ca(2+)-store depletion in RBL-2H3 cells and human salivary gland cells, HSG and HSY. J Membr Biol; 2004 Jul 15;200(2):93-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct Ca(2+)-permeable cation currents are activated by internal Ca(2+)-store depletion in RBL-2H3 cells and human salivary gland cells, HSG and HSY.
  • Here we have compared the properties of SOC currents ( I(SOC)) in human submandibular glands cells (HSG) and human parotid gland cells (HSY) with I(CRAC) (Ca(2+) release-activated Ca(2+) current) in RBL cells.
  • Internal Ca(2+) store-depletion with IP(3) or thapsigargin activated cation channels in all three cell types.
  • Washout of Gd(3+) induced partial recovery in HSY and HSG but not RBL cells.
  • I(CRAC )in RBL cells displayed strong inward rectification with E(rev)(Ca) = >+90 mV and E(rev) (Na) = +60 mV.
  • HSY cells displayed a linear current with E(rev) = +5 mV, which was similar in Ca(2+)- or Na(+)-containing medium. pCa/ pNa was >500, 40, and 4.6 while pCs / pNa was 0.1,1, and 1.3, for RBL, HSG, and HSY cells, respectively.
  • Evidence for anomalous mole fraction behavior of Ca(2+)/Na(+) permeation was obtained with RBL and HSG cells but not HSY cells.
  • Additionally, channel inactivation with Ca(2+) + Na(+) or Na(+) in the bath was different in the three cell types.
  • In aggregate, these data demonstrate that distinct store-dependent cation currents are stimulated in RBL, HSG, and HSY cells.
  • [MeSH-minor] Cadmium / pharmacology. Calcium Signaling / drug effects. Calcium Signaling / physiology. Cations / metabolism. Cell Line. Enzyme Inhibitors / pharmacology. Humans. Inositol 1,4,5-Trisphosphate / pharmacology. Ion Channel Gating / drug effects. Membrane Potentials / drug effects. Patch-Clamp Techniques. Sarcoplasmic Reticulum / metabolism. Thapsigargin / pharmacology

  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Physiol. 1999 Jul 15;518 Pt 2:345-58 [10381584.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:521-55 [11031246.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3403-11 [10652333.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):323-36 [12765679.001]
  • [Cites] Am J Physiol. 1998 Aug;275(2 Pt 1):C571-80 [9688612.001]
  • [Cites] Physiol Rev. 2001 Oct;81(4):1415-59 [11581493.001]
  • [Cites] Nat Cell Biol. 2002 Nov;4(11):E263-72 [12415286.001]
  • [Cites] Pflugers Arch. 2002 Mar;443(5-6):892-902 [11889590.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11337-43 [12536150.001]
  • [Cites] J Gen Physiol. 2002 May;119(5):487-507 [11981025.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27799-805 [10882720.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21649-54 [12686562.001]
  • [Cites] Hepatology. 2001 Apr;33(4):938-47 [11283858.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40088-96 [12874277.001]
  • [Cites] Endocr Rev. 1993 Oct;14(5):610-31 [8262009.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):433-40 [12765688.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33295-304 [9837902.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33704-10 [12093812.001]
  • [Cites] Crit Rev Oral Biol Med. 2000;11(1):4-25 [10682899.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):451-61 [12765690.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):379-91 [12543097.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26158-63 [10851243.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):26950-8 [12011062.001]
  • [Cites] Biochem Soc Trans. 2003 Oct;31(Pt 5):925-9 [14505450.001]
  • [Cites] J Physiol. 2003 Mar 1;547(Pt 2):333-48 [12576497.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):345-56 [12765681.001]
  • [Cites] Neuron. 2001 Mar;29(3):645-55 [11301024.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):121-7 [11175743.001]
  • [Cites] Nature. 1992 Jan 23;355(6358):353-6 [1309940.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21617-23 [11943785.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):311-21 [12765678.001]
  • [Cites] J Biol Chem. 1998 Jun 12;273(24):14925-32 [9614097.001]
  • [Cites] J Membr Biol. 2001 Jun 1;181(3):185-93 [11420605.001]
  • [Cites] Physiol Rev. 1997 Oct;77(4):901-30 [9354808.001]
  • [Cites] Mol Cell. 2002 Apr;9(4):739-50 [11983166.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):29891-8 [11395504.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Oct;1(1):11-21 [11413485.001]
  • [Cites] Bioessays. 1999 Jan;21(1):38-46 [10070252.001]
  • [Cites] Curr Opin Neurobiol. 2003 Jun;13(3):298-307 [12850214.001]
  • (PMID = 15520907.001).
  • [ISSN] 0022-2631
  • [Journal-full-title] The Journal of membrane biology
  • [ISO-abbreviation] J. Membr. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Cations; 0 / Enzyme Inhibitors; 00BH33GNGH / Cadmium; 67526-95-8 / Thapsigargin; 85166-31-0 / Inositol 1,4,5-Trisphosphate; SY7Q814VUP / Calcium
  •  go-up   go-down


20. Malaviya R, Uckun FM: Leflunomide metabolite analogue alpha-cyano-beta-hydroxy-beta-methyl-N-[3-(trifluoromethyl)phenyl]propenamide inhibits IgE/FcepsilonRI receptor-mediated mast cell leukotriene release and allergic asthma in mice. Am J Ther; 2001 Sep-Oct;8(5):309-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed that the novel LFM analogue, alpha-cyano-beta-hydroxy-beta-methyl-N-[3-(trifluoromethyl) phenyl]propenamide (LFM-A8), is a more potent inhibitor than LFM of IgE/FcepsilonRI receptor-mediated LTC4 release from RBL-2H3 rat mast cells.
  • Treatment of ovalbumin (OVA)-sensitized mice with LFM-A8 prevented the development of airway hyperresponsiveness to methacholine in a dose-dependent fashion.
  • Therefore further development of compound LFM-A8 may provide the basis for new and effective treatment programs for severe allergic disorders, including allergic asthma.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Isoxazoles / pharmacology. Mast Cells / drug effects
  • [MeSH-minor] Animals. Asthma / drug therapy. Asthma / physiopathology. Leukotriene C4 / metabolism. Mice. Mice, Inbred BALB C. Receptors, IgE / drug effects. Structure-Activity Relationship

  • Hazardous Substances Data Bank. LEFLUNOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11550070.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Isoxazoles; 0 / Receptors, IgE; 2CU6TT9V48 / Leukotriene C4; G162GK9U4W / leflunomide
  •  go-up   go-down


21. Lim BO, Lee JH, Ko NY, Mun SH, Kim JW, Kim DK, Kim JD, Kim BK, Kim HS, Her E, Lee HY, Choi WS: Polygoni cuspidati radix inhibits the activation of Syk kinase in mast cells for antiallergic activity. Exp Biol Med (Maywood); 2007 Dec;232(11):1425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The extract of PR exhibited potent inhibitory activity in mast cells; its IC50 values were 62 +/- 2.1 microg/ml for RBL-2H3 mast cells and 46 +/- 3.2 microg/m for bone marrow-derived mast cells by antigen stimulation, and it also suppressed the expression of tumor necrosis factor-alpha and interleukin-4 in RBL-2H3 cells.
  • [MeSH-major] Anaphylaxis / drug therapy. Anti-Allergic Agents / pharmacology. Fallopia japonica. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Mast Cells / enzymology. Plant Extracts / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Animals. Antigens / pharmacology. Bone Marrow Cells / enzymology. Bone Marrow Cells / pathology. Cell Line. Disease Models, Animal. Enzyme Activation / drug effects. Histamine / metabolism. Inflammation / drug therapy. Inflammation / enzymology. Interleukin-4 / biosynthesis. MAP Kinase Kinase 4 / metabolism. Male. Mice. Mice, Inbred ICR. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction / drug effects. Tumor Necrosis Factor-alpha / biosynthesis

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • Hazardous Substances Data Bank. HISTAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040066.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Antigens; 0 / Intracellular Signaling Peptides and Proteins; 0 / Plant Extracts; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 820484N8I3 / Histamine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.12.2 / MAP Kinase Kinase 4
  •  go-up   go-down


22. Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, Votta G, Masucci MT, Arra C, Franco R, De Rosa M, Stoppelli MP, Pavone V: Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther; 2009 Sep;8(9):2708-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
  • The urokinase-type plasminogen activator receptor (uPAR) plays a central role in sustaining the malignant phenotype and promoting tumor metastasis.
  • Here, we describe the generation of new peptide inhibitors of cell migration and invasion derived from SRSRY by a drug design approach.
  • Fluorescein-RERF associates with very high affinity to RBL-2H3 rat basophilic leukemia cells expressing the human formyl peptide receptor (FPR).
  • The involvement of vitronectin receptor is further supported by the findings that 100 pmol/L RERF selectively inhibits vitronectin-dependent RBL-2H3 cell migration and prevents SRSRY-triggered uPAR/alphav association.
  • Our findings indicate that RERF effectively prevents malignant cell invasion in vivo with no signs of toxicity and may represent a promising prototype drug for anticancer therapy.
  • [MeSH-major] Cell Movement / drug effects. Lung Neoplasms / secondary. Neoplasm Metastasis / prevention & control. Peptide Fragments / pharmacology. Receptors, Urokinase Plasminogen Activator / chemistry

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706734.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / Receptors, Urokinase Plasminogen Activator
  •  go-up   go-down


23. Lee SH, Shin YW, Bae EA, Lee B, Min S, Baek NI, Chung HG, Kim NJ, Kim DH: Lactic acid bacteria increase antiallergic effect of Artemisia princeps pampanini SS-1. Arch Pharm Res; 2006 Sep;29(9):752-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these fermented agents, SS-1 extract fermented with Bifidobacterium infantis K-525 (F-SS-1) most effectively inhibited the release of P-hexosamindase from RBL-2H3 cells induced IgE.
  • In IgE-induced RBL-2H3 cells, F-SS-1 inhibited proinflammatory cytokines IL-6 and TNF-alpha mRNA expression.
  • [MeSH-minor] Animals. Cell Line. Feces / microbiology. Female. Fermentation. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Passive Cutaneous Anaphylaxis. Plant Extracts / pharmacology. Pruritus / chemically induced. Pruritus / drug therapy. Reverse Transcriptase Polymerase Chain Reaction. beta-N-Acetylhexosaminidases / metabolism. p-Methoxy-N-methylphenethylamine / adverse effects

  • Hazardous Substances Data Bank. LACTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17024848.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Plant Extracts; 33X04XA5AT / Lactic Acid; 4091-50-3 / p-Methoxy-N-methylphenethylamine; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


24. Cho YS, Kim CH, Surh JH, Kang NS, Yoo SE, Cheon HG: Identification of 4-[4-(4-fluoro-phenyl)-thiazol-2-ylamino]-2,6-dimethyl-phenol (KR-33749) as an inhibitor of 5-lipoxygenase with potent antiinflammatory activity. Pharmacology; 2010;86(2):65-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 5-LO enzyme activity was assayed using insect cell lysates overexpressing rat 5-LO.
  • The leukotriene B(4) (LTB(4)) level was assayed in rat basophilic leukemia (RBL-1) cell line.
  • RESULTS: KR-33749 inhibited 5-LO activity with an IC(50) value of 70.5 +/- 6.0 nmol/l in parallel with LTB(4) inhibition in RBL-1 cells.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Arachidonate 5-Lipoxygenase / metabolism. Lipoxygenase Inhibitors / pharmacology. Lipoxygenase Inhibitors / therapeutic use. Thiazoles / pharmacology. Thiazoles / therapeutic use. Xylenes / pharmacology. Xylenes / therapeutic use
  • [MeSH-minor] Animals. Arachidonic Acid / toxicity. Cell Line, Tumor. Dermatitis, Atopic / drug therapy. Dermatitis, Atopic / immunology. Dermatitis, Atopic / pathology. Dinitrochlorobenzene / toxicity. Dose-Response Relationship, Drug. Edema / prevention & control. Isoenzymes / antagonists & inhibitors. Leukotriene B4 / metabolism. Leukotriene B4 / secretion. Male. Mice. Mice, Inbred BALB C. Osmolar Concentration. Rats. Recombinant Proteins / antagonists & inhibitors. Skin / drug effects. Skin / pathology. Skin Diseases / drug therapy. Time Factors

  • Hazardous Substances Data Bank. 1-CHLORO-2,4-DINITROBENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20639685.001).
  • [ISSN] 1423-0313
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 4-(4-(4-fluorophenyl)thiazol-2-ylamino)-2,6-dimethylphenol; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Isoenzymes; 0 / Lipoxygenase Inhibitors; 0 / Recombinant Proteins; 0 / Thiazoles; 0 / Xylenes; 1HGW4DR56D / Leukotriene B4; 27YG812J1I / Arachidonic Acid; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; GE3IBT7BMN / Dinitrochlorobenzene
  •  go-up   go-down


25. Jeon JH, Kwon SC, Park D, Shin S, Jeong JH, Park SY, Hwang SY, Kim YB, Joo SS: Anti-allergic effects of white rose petal extract and anti-atopic properties of its hexane fraction. Arch Pharm Res; 2009 Jun;32(6):823-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the cell level, the hexane fraction markedly inhibited beta-hexosaminidase release from RBL-2H3 mast cells and suppressed the expressions of mRNA interferon-gamma and interleukin-4 cytokines produced by T helper cells (type 1 and 2).
  • These results strongly support that the hexane fraction may have an effect on atopic dermatitis, as these 2 cell types play central roles in the pathogenesis of atopic dermatitis.
  • In conclusion, these results suggest that either the hexane fraction or one of its components may be beneficial for the treatment of allergic diseases, including atopic dermatitis.
  • [MeSH-major] Anti-Allergic Agents / pharmacology. Hexanes / pharmacology. Hypersensitivity, Immediate / drug therapy. Phytotherapy. Plant Extracts / pharmacology. Rosa
  • [MeSH-minor] Anaphylaxis / chemically induced. Anaphylaxis / drug therapy. Animals. Cells, Cultured. Cytokines / metabolism. Drug Evaluation, Preclinical. Flowers / chemistry. Histamine / pharmacology. Male. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Passive Cutaneous Anaphylaxis / drug effects. Spleen / drug effects. Spleen / metabolism. beta-N-Acetylhexosaminidases / secretion. p-Methoxy-N-methylphenethylamine / pharmacology

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19557358.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Cytokines; 0 / Hexanes; 0 / Plant Extracts; 4091-50-3 / p-Methoxy-N-methylphenethylamine; 820484N8I3 / Histamine; EC 3.2.1.52 / beta-N-Acetylhexosaminidases
  •  go-up   go-down


26. Qu X, Li Y, Liu J, Xu L, Zhang Y, Hu X, Hou K, Liu Y: Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation. Mol Cell Biochem; 2010 Jul;340(1-2):107-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation.
  • The ubiquitin ligase Cbl-b is a negative regulator of the PI3K/Akt pathway, the survival pathway implicated in chemotherapy resistance.
  • In this study, VP-16-induced RBL-2H3 cells apoptosis was accompanied by the activation of Akt and ERK.
  • The consistent results were also showed in the process of Ara-c treatment.
  • These observations indicate that Cbl-b promotes RBL-2H3 apoptosis induced by VP-16 or Ara-c, probably through inhibition of Akt and activation of ERK.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Antimetabolites, Antineoplastic / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Leukemia, Basophilic, Acute / enzymology. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-cbl / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival. Cytarabine / pharmacology. Dose-Response Relationship, Drug. Enzyme Activation. Enzyme Inhibitors / pharmacology. Etoposide / pharmacology. Inhibitory Concentration 50. Mutation. Rats. Time Factors. Transfection

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2006 Nov 1;177(9):5980-9 [17056522.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1779-86 [14604964.001]
  • [Cites] Nature. 2000 Jan 13;403(6766):211-6 [10646608.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1921-30 [17581609.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1203-11 [17283156.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2367-77 [7784085.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4872-8 [11087752.001]
  • [Cites] J Immunol. 2008 Oct 15;181(8):5331-9 [18832689.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1022-4 [17475912.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 29;367 (1):183-9 [18164258.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6271-80 [18676851.001]
  • [Cites] Eur J Haematol. 2003 Apr;70(4):219-24 [12656744.001]
  • [Cites] FEBS Lett. 2009 Jul 7;583(13):2255-62 [19508871.001]
  • [Cites] J Pathol. 2009 Jun;218(2):248-55 [19274672.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31498-507 [16014620.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):677-86 [15916691.001]
  • [Cites] Biochim Biophys Acta. 2006 Sep;1763(9):958-68 [16905201.001]
  • [Cites] Oncogene. 2002 Feb 21;21(9):1423-33 [11857085.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10 ):3141-9 [18852117.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):870-5 [11526404.001]
  • [Cites] Immunity. 2007 May;26(5):567-78 [17493844.001]
  • [Cites] Nature. 2000 Jan 13;403(6766):216-20 [10646609.001]
  • [Cites] Mutagenesis. 2006 Mar;21(2):105-14 [16500949.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Aug 24;213(3):837-44 [7654245.001]
  • [Cites] Neoplasia. 2008 Oct;10 (10 ):1083-91 [18813358.001]
  • (PMID = 20177738.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; EC 2.3.2.27 / Proto-Oncogene Proteins c-cbl; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 6.3.2.19 / Cblb protein, rat
  •  go-up   go-down


27. Bae EA, Min SW, Lee B, Kim NJ, Baek NI, Han EJ, Chung HG, Kim DH: Antiasthmic effect of fermented Artemisia princeps in asthmic mice induced by ovalbumin. J Microbiol Biotechnol; 2007 Sep;17(9):1554-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nonetheless, AP and FAP both inhibited the mRNA expression of IL-6 and TNF-alpha in IgE-induced RBL-2H3 cells.
  • [MeSH-major] Anti-Allergic Agents / pharmacology. Artemisia / chemistry. Asthma / drug therapy. Bifidobacterium / metabolism. Lung / drug effects
  • [MeSH-minor] Animals. Fermentation. Hypersensitivity / prevention & control. Immunoglobulin E. Interleukin-4. Interleukin-6. Mice. Mice, Inbred BALB C. Models, Animal. Ovalbumin / blood. Ovalbumin / immunology. Plant Extracts / pharmacology. Pruritus / chemically induced. Pruritus / drug therapy. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Asthma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18062237.001).
  • [ISSN] 1017-7825
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Interleukin-6; 0 / Plant Extracts; 0 / RNA, Messenger; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E; 9006-59-1 / Ovalbumin
  •  go-up   go-down


28. Abe M, Shibata K, Urata H, Sakata N, Katsuragi T: Induction of leukotriene C4 synthase after the differentiation of rat basophilic leukemia cells with retinoic acid and a low dose of actinomycin D and its suppression with methylprednisolone. J Cell Physiol; 2003 Jul;196(1):154-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of leukotriene C4 synthase after the differentiation of rat basophilic leukemia cells with retinoic acid and a low dose of actinomycin D and its suppression with methylprednisolone.
  • LTC(4) S activity in rat basophilic leukemia-1 (RBL-1) cells increased after culture in the presence of retinoic acid (RA) analogues, which was inhibited by cycloheximide or actinomycin D (ACD).
  • The suppression of LTC(4) S with MP showed a dependent manner on the time-point and duration of MP-treatment after RA-addition which was correlated with reduction in LTC(4) S mRNA and protein.
  • In consideration of RA-differentiation therapy, it may be of pathophysiological relevance that the antineoplastic agents potentiate RA-induced, steroid-sensitive, induction of LTC(4) S in RBL-1 cells.
  • [MeSH-major] Cell Differentiation / drug effects. Dactinomycin / antagonists & inhibitors. Dactinomycin / pharmacology. Glutathione Transferase / biosynthesis. Leukemia, Basophilic, Acute / enzymology. Methylprednisolone / pharmacology. Tretinoin / pharmacology
  • [MeSH-minor] Animals. Calcimycin / pharmacology. Cell Line. Cell Size / drug effects. Chymases. Cycloheximide / pharmacology. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Histamine / metabolism. Interleukin-4 / genetics. Lipoxygenase / metabolism. RNA Stability / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Serine Endopeptidases / metabolism. Solubility. Time Factors. Transcription, Genetic / drug effects

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12767051.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 1CC1JFE158 / Dactinomycin; 207137-56-2 / Interleukin-4; 37H9VM9WZL / Calcimycin; 5688UTC01R / Tretinoin; 820484N8I3 / Histamine; 98600C0908 / Cycloheximide; EC 1.13.11.12 / Lipoxygenase; EC 2.5.1.18 / Glutathione Transferase; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.39 / Chymases; EC 4.4.1.20 / leukotriene-C4 synthase; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


29. Tries S, Neupert W, Laufer S: The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res; 2002 Mar;51(3):135-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We examined the effects of ML3000 and several non-steroidal antiinflammatory drugs (NSAIDs) on the synthesis of products of 5-LOX (LTB4, LTC4) and COX-1/2 (TXB2, PGE2) in vitro and ex vivo in order to further elucidate the mechanism of action of ML3000.
  • 5-lipoxygenase inhibition was further tested in a basophilic leukemia cell assay using RBL-1 cells.
  • In carrageenan induced rat paw edema, ML3000 and indomethacin completely blocked the formation of PGE2 in the inflamed tissue.
  • 5-LOX inhibition in the inflamed rat colon was investigated by measuring LTB4 synthesis.
  • MK-886 and ML3000 at 10 mg/kg p.o. reduced LTB4 production to 29.8 +/- 4.9 and 30.1 +/- 2.8 pg/mg tissue as compared to control (54.2 +/- 7.4 mg/kg tissue).
  • LTB4 levels in the rat stomach were comparable to control (2.5 +/- 0.4 pg/mg protein) after oral administration of ML3000 (10, 30, 100 mg/kg), whereas oral treatment with indomethacin (0.3, 1, 3 mg/kg) or diclofenac (1, 3 mg/kg) increased LTB4 up to 9.2 +/- 2.3 or 8.9 +/- 1.6 pg/mg protein.
  • [MeSH-minor] Adult. Animals. Colon / drug effects. Colon / metabolism. Edema / drug therapy. Edema / metabolism. Humans. Leukotriene B4 / biosynthesis. Leukotriene C4 / biosynthesis. Male. Rats. Rats, Sprague-Dawley. Rats, Wistar. Stomach / drug effects. Stomach / metabolism. Thromboxane B2 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12005204.001).
  • [ISSN] 1023-3830
  • [Journal-full-title] Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  • [ISO-abbreviation] Inflamm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Acetates; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 0 / Lipoxygenase Inhibitors; 0 / Pyrroles; 156897-06-2 / licofelone; 1HGW4DR56D / Leukotriene B4; 2CU6TT9V48 / Leukotriene C4; 54397-85-2 / Thromboxane B2
  •  go-up   go-down


30. Wallmann J, Proell M, Stepanoska T, Hantusch B, Pali-Schöll I, Thalhamer T, Thalhamer J, Jensen-Jarolim E, Hartl A: A mimotope gene encoding the major IgE epitope of allergen Phl p 5 for epitope-specific immunization. Immunol Lett; 2009 Jan 29;122(1):68-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an RBL assay, mimotope-specific IgG antibodies were able to prevent cross-linking of allergen-specific IgE by Phl p 5.
  • We therefore suggest that mimotope gene vaccines are potential candidates for epitope-specific immunotherapy of type I allergy.
  • [MeSH-minor] Animals. Biomimetic Materials. Cell Degranulation / genetics. Cell Degranulation / immunology. Cell Line, Tumor. Desensitization, Immunologic. Female. Genetic Engineering. Genetic Therapy. Immunoglobulin G / blood. Interferon-gamma / secretion. Lymphocyte Activation / genetics. Lymphocyte Activation / immunology. Mice. Mice, Inbred BALB C. Pollen. Rats

  • MedlinePlus Health Information. consumer health - Hay Fever.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2001 Jul 27;502(1-2):46-52 [11478946.001]
  • [Cites] FASEB J. 2001 Nov;15(13):2524-6 [11641259.001]
  • [Cites] Vaccine. 2002 Aug 19;20(25-26):3148-54 [12163266.001]
  • [Cites] Clin Exp Allergy. 2002 Nov;32(11):1583-8 [12569978.001]
  • [Cites] Mol Immunol. 2003 May;39(14):847-54 [12686500.001]
  • [Cites] J Immunol. 2003 Aug 15;171(4):1999-2005 [12902504.001]
  • [Cites] Microbes Infect. 2003 Sep;5(11):939-46 [12941385.001]
  • [Cites] Clin Exp Allergy. 2003 Sep;33(9):1171-4 [12956735.001]
  • [Cites] J Allergy Clin Immunol. 2003 Nov;112(5):915-22 [14610480.001]
  • [Cites] Methods. 2004 Mar;32(3):321-7 [14962767.001]
  • [Cites] Methods. 2004 Mar;32(3):328-39 [14962768.001]
  • [Cites] Adv Exp Med Biol. 1989;251:215-8 [2481962.001]
  • [Cites] Gene. 1995 Mar 21;155(1):61-5 [7698668.001]
  • [Cites] J Virol. 1996 Sep;70(9):6119-25 [8709236.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2278-84 [9036975.001]
  • [Cites] J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):107-13 [9893193.001]
  • [Cites] Allergy. 1999 Jun;54(6):552-61 [10435468.001]
  • [Cites] FASEB J. 1999 Sep;13(12):1586-92 [10463950.001]
  • [Cites] J Allergy Clin Immunol. 2004 Dec;114(6):1294-300 [15577826.001]
  • [Cites] Curr Drug Targets Inflamm Allergy. 2005 Oct;4(5):585-97 [16248827.001]
  • [Cites] Mol Immunol. 2006 Mar;43(9):1454-61 [16150491.001]
  • [Cites] Allergy. 2006 Jul;61(7):828-35 [16792580.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jul;118(1):269-76 [16815165.001]
  • [Cites] J Allergy Clin Immunol. 2006 Sep;118(3):734-41 [16950295.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10567-75 [17079481.001]
  • [Cites] Mol Immunol. 2007 Mar;44(8):1879-87 [17070909.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3406-11 [17409451.001]
  • [Cites] Vaccine. 2000 Mar 6;18(17):1725-9 [10699319.001]
  • [Cites] Infect Immun. 2000 Oct;68(10):5914-9 [10992502.001]
  • [Cites] FASEB J. 2000 Nov;14(14):2177-84 [11053238.001]
  • [Cites] Int Arch Allergy Immunol. 2001 Jan-Mar;124(1-3):395-7 [11307026.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1558-65 [11466377.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6501-8 [17975163.001]
  • [Cites] Mol Immunol. 2008 Mar;45(5):1308-17 [17964653.001]
  • [Cites] Methods Mol Med. 2008;138:271-83 [18612616.001]
  • (PMID = 19111573.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / F 1808
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunodominant Epitopes; 0 / Immunoglobulin G; 0 / Phl p V protein, Phleum pratense; 0 / Plant Proteins; 37341-29-0 / Immunoglobulin E; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2999763; NLM/ UKMS32994
  •  go-up   go-down


31. Oka T, Fujimoto M, Nagasaka R, Ushio H, Hori M, Ozaki H: Cycloartenyl ferulate, a component of rice bran oil-derived gamma-oryzanol, attenuates mast cell degranulation. Phytomedicine; 2010 Feb;17(2):152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IgE-targeting therapy could provide significant progress in the treatment of allergic inflammation.
  • CAF and gamma-oryzanol also inhibited the degranulation of DNP-IgE sensitized RBL-2H3 mast cells stimulated with anti-DNP-HSA.
  • [MeSH-major] Cell Degranulation / drug effects. Coumaric Acids / pharmacology. Hypersensitivity / drug therapy. Mast Cells / drug effects. Phenylpropionates / pharmacology. Plant Extracts / pharmacology. Plant Oils / chemistry
  • [MeSH-minor] Animals. Antibodies, Anti-Idiotypic / blood. Dinitrophenols. Enzyme-Linked Immunosorbent Assay. Immunoglobulin E / blood. Inflammation / blood. Inflammation / drug therapy. Male. Oryza / chemistry. Passive Cutaneous Anaphylaxis / drug effects. Phytotherapy. Rats. Rats, Sprague-Dawley. Receptors, IgE / metabolism. Serum Albumin. Skin / drug effects

  • MedlinePlus Health Information. consumer health - Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19577449.001).
  • [ISSN] 1618-095X
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Coumaric Acids; 0 / Dinitrophenols; 0 / Phenylpropionates; 0 / Plant Extracts; 0 / Plant Oils; 0 / Receptors, IgE; 0 / Serum Albumin; 0 / anti-IgE antibodies; 0 / cycloartenyl ferulate; 0 / dinitrophenyl-human serum albumin conjugate; 37341-29-0 / Immunoglobulin E; 68553-81-1 / rice bran oil; SST9XCL51M / gamma-oryzanol
  •  go-up   go-down


32. Yang P, Collin P, Madden T, Chan D, Sweeney-Gotsch B, McConkey D, Newman RA: Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate; 2003 Jun 1;55(4):281-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 12-MTA was evaluated by MTT assay for its ability to inhibit cell proliferation in various cancer types.
  • Furthermore, alteration of eicosanoid metabolism by 12-MTA was examined in PC3 and RBL-1 cells and in purified lipoxygenase (LOX) and cyclooxygenase (COX) enzymes.
  • This agent may be a novel adjunctive therapy for selected malignancies including prostate cancer.
  • [MeSH-major] Fatty Acids / pharmacology. Lipoxygenase Inhibitors. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / enzymology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Arachidonate 5-Lipoxygenase / metabolism. Caspase 3. Caspases / metabolism. Cell Division / drug effects. Cyclooxygenase Inhibitors / pharmacology. Enzyme Activation / drug effects. Enzyme Inhibitors / pharmacology. Female. Flow Cytometry. Growth Inhibitors / pharmacology. Humans. Hydroxyeicosatetraenoic Acids / metabolism. Male. Microscopy, Electron, Scanning. Prostaglandin-Endoperoxide Synthases / metabolism. Rats. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12712407.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Enzyme Inhibitors; 0 / Fatty Acids; 0 / Growth Inhibitors; 0 / Hydroxyeicosatetraenoic Acids; 0 / Lipoxygenase Inhibitors; 467RNW8T91 / 5-hydroxy-6,8,11,14-eicosatetraenoic acid; 5502-94-3 / aseanostatin P5; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


33. Zhu J, Wang O, Ruan L, Hou X, Cui Y, Wang JM, Le Y: The green tea polyphenol (-)-epigallocatechin-3-gallate inhibits leukocyte activation by bacterial formylpeptide through the receptor FPR. Int Immunopharmacol; 2009 Aug;9(9):1126-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment of human monocytic cells or FPR-transfected rat basophilic leukemia cells (ETFR cells) with EGCG significantly inhibited fMLF-induced chemotaxis.
  • [MeSH-minor] Animals. Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors. Camellia sinensis / immunology. Cell Line, Tumor. Cell Movement / drug effects. Cell Movement / immunology. Flavonoids / pharmacology. Humans. Inflammation. Injections, Intraperitoneal. Leukemia, Basophilic, Acute / blood. Leukemia, Basophilic, Acute / drug therapy. Leukemia, Basophilic, Acute / immunology. Mice. Rats. Receptors, Formyl Peptide / genetics. Receptors, Formyl Peptide / immunology. Receptors, Formyl Peptide / metabolism. Signal Transduction / drug effects. Signal Transduction / immunology. Transfection. Transgenes

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19426837.001).
  • [ISSN] 1878-1705
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Antioxidants; 0 / Flavonoids; 0 / Receptors, Formyl Peptide; 59880-97-6 / N-Formylmethionine Leucyl-Phenylalanine; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


34. Lee HY, Kim MK, Park KS, Shin EH, Jo SH, Kim SD, Jo EJ, Lee YN, Lee C, Baek SH, Bae YS: Serum amyloid A induces contrary immune responses via formyl peptide receptor-like 1 in human monocytes. Mol Pharmacol; 2006 Jul;70(1):241-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stimulation of formyl peptide receptor-like-1-expressing RBL-2H3 cells, but not of vector-expressing RBL-2H3 cells with serum amyloid A, induced mitogen-activated protein kinases activation and the accumulation of the RNAs of these two cytokines.
  • [MeSH-major] Monocytes / drug effects. Receptors, Formyl Peptide / metabolism. Serum Amyloid A Protein / pharmacology
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Chromones / pharmacology. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Enzyme Inhibitors / pharmacology. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Extracellular Signal-Regulated MAP Kinases / metabolism. Flavonoids / pharmacology. Humans. Imidazoles / pharmacology. Interleukin-10 / biosynthesis. Interleukin-10 / genetics. Morpholines / pharmacology. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. Nitriles / pharmacology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation / drug effects. Pyridines / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sulfones / pharmacology. Tumor Necrosis Factor-alpha / biosynthesis. Tumor Necrosis Factor-alpha / genetics. p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569709.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / 3-(4-methylphenylsulfonyl)-2-propenenitrile; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Morpholines; 0 / NF-kappa B; 0 / Nitriles; 0 / Pyridines; 0 / RNA, Messenger; 0 / Receptors, Formyl Peptide; 0 / SB 203580; 0 / Serum Amyloid A Protein; 0 / Sulfones; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down






Advertisement